Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "NCEs"

2152 News Found

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant
News | September 18, 2024

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant

The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD


Zydus announces licensing and supply agreement for two Gadolinium based MRI injectable
News | September 14, 2024

Zydus announces licensing and supply agreement for two Gadolinium based MRI injectable

Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market


Briefs: RPG Life Sciences and Lasa Supergenerics
News | September 14, 2024

Briefs: RPG Life Sciences and Lasa Supergenerics

Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline


Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0
News | September 12, 2024

Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0

Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign


Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
Diagnostic Center | September 11, 2024

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast

ALS patients experience neuroinflammation and rapid neurodegeneration


Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9
Diagnostic Center | September 11, 2024

Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9

The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9


AVEO Oncology announces acceptance of late-breaking oral presentation of TiNivo-2 results at ESMO 2024
Diagnostic Center | September 05, 2024

AVEO Oncology announces acceptance of late-breaking oral presentation of TiNivo-2 results at ESMO 2024

Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab


Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
News | September 05, 2024

Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business

TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry


AstraZeneca advances ambition to improve standards of care in multiple cancer types
News | September 04, 2024

AstraZeneca advances ambition to improve standards of care in multiple cancer types

Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer


NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis
News | September 04, 2024

NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage